Consolidated Statements of Cash Flows - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities
Net Loss		$ (26,958)	$ (63,150)
Adjustments to reconcile net income (loss) to net cash used in operating activities
Depreciation and amortization		10,516	8,450
Amortization of debt issuance costs		609	787
Amortization of postcombination compensation		1,661	0
Deferred income taxes		2,734	384
Amortization of operating right-of-use assets	[1]	8,855	8,289
(Gain) Loss on change in fair value of derivatives		(243)	10,204
Equity-based compensation and NCI rebalancing		14,422	4,874
Equity in (income) loss of affiliate		(153)	259
Loss (gain) on sale and abandonment of property and equipment		4,496	(289)
Bargain purchase gain on acquisition of physician practice		(514)	0
Changes in operating assets and liabilities, net of reverse recapitalization:
Patient accounts receivable, net		(771)	6,947
Inventories	[2]	(13,671)	(8,090)
Prepaid expenses and other current assets		(3,957)	(1,607)
Other receivables		(20,739)	(5,759)
Other assets		(13,126)	(2,649)
Accounts payable	[3]	39,490	20,067
Accrued compensation related costs		8,029	3,944
Accrued other		(6,112)	5,495
Operating lease liabilities	[4]	(6,925)	(7,754)
Other long-term liabilities		(2,586)	1,480
Net cash used in operating activities		(4,943)	(18,118)
Cash flows from investing activities
Purchases of property and equipment		(20,954)	(12,283)
Proceeds from disposals of property and equipment		218	704
Purchases of marketable securities		(28,636)	(67,395)
Proceeds from sales of marketable securities		54,736	42,320
Acquisition of physician practices		(6,712)	0
Issuance of notes receivable - related parties		(1,925)	(55)
Collections on notes receivable - related parties		862	1,175
Net cash used in investing activities		(2,411)	(35,534)
Cash flows from financing activities
Repayments of long-term debt		(3,498)	0
Proceeds from reverse recapitalization		0	1,493
Repurchases of Class A Common Stock		(368)	(89)
Payment of tax withholding obligation on net RSU settlements		(3,258)	0
Class A and A-1 preferred returns and tax distributions		0	(9,480)
Repayments on finance leases		(1,212)	(593)
Issuance of redeemable convertible Class C Units		0	64,996
Issuance of Class A Common Stock	[5]	50,000	0
Cash paid for debt financing costs		0	(446)
Series A Preferred Stock offering costs		0	(750)
Contribution from noncontrolling interest		0	134
Net cash provided by financing activities		41,664	55,265
Net increase (decrease) in cash and cash equivalents		34,310	1,613
Beginning of period		28,539	26,926
End of period		62,849	28,539
Supplemental consolidated cash flow information
Cash paid for interest		5,743	5,847
Supplemental noncash investing and financing activities
Unpaid offering costs relating to the reverse recapitalization		0	2,745
Right-of-use assets and lease liabilities removed in termination of lease		0	2,128
Promissory note issued in connection with acquisition of physician practices		(6,550)	0
Promissory note issued in connection with asset acquisition		(1,848)	0
Noncash consideration paid by assumption of note for purchase of physician practice		(4,530)	0
Deemed dividend for Series A Preferred Stock extinguishment		0	2,089
Changes in accounts payable for capital additions to property and equipment		0	1,131
Other		(380)	0
Forgiveness on note receivable related-party		$ 255	$ 0

[1] Includes related party amortization of operating right-of-use assets of $1,990 and $2,146 for the years ended December 31, 2024 and 2023, respectively.

[2] Includes changes in related party balances of ($6,110) and $(7,688) for the years ended December 31, 2024 and 2023, respectively.

[3] Includes changes in related party balances of $35,046 and $18,744 for the years ended December 31, 2024 and 2023, respectively.

[4] Includes changes in related party balances of ($2,522) and ($2,381) for the years ended December 31, 2024 and 2023, respectively. (5)Net of $1,000 of issuance costs.

[5] Net of $1,000 of issuance costs.